Psoriasis comorbidities

被引:196
作者
Gottlieb, Alice B. [1 ]
Chao, Chun [2 ]
Dann, Frank [3 ]
机构
[1] Tufts Univ, New England Med Ctr, Boston, MA 02111 USA
[2] Univ Calif Los Angeles, Dept Epidemiol, Los Angeles, CA USA
[3] Amgen Inc, Thousand Oaks, CA 91320 USA
关键词
cardiovascular disease; comorbidities; metabolic syndrome; obesity; psoriasis;
D O I
10.1080/09546630701364768
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Psoriasis is a chronic and debilitating inflammatory disease associated with serious comorbidities. Psoriasis can have a significant impact on a patient's quality of life and is associated with loss of productivity, depression, and an increased prevalence of malignancy. Emerging comorbidities of psoriasis include cardiovascular disease and metabolic syndrome. Psoriasis patients have an increased prevalence of the core components of metabolic syndrome, including obesity, dyslipidemia, and insulin resistance. The relationship between psoriasis and comorbidities such as metabolic syndrome and cardiovascular disease is likely linked to the underlying chronic inflammatory nature of psoriasis. The molecular mechanisms involved in psoriasis-associated dysregulation of metabolic function are believed to be due, in large part, to the action of increased levels of proinflammatory factors, such as tumor necrosis factor-alpha, that are central to the pathogenesis of psoriasis. Recent studies investigating the effects of tumor necrosis factor antagonists on the treatment of cardiovascular disease and metabolic syndrome support this concept.
引用
收藏
页码:5 / 21
页数:17
相关论文
共 210 条
[1]   Assessment of depression in subjects with psoriasis vulgaris and lichen planus [J].
Akay, A ;
Pekcanlar, A ;
Bozdag, KE ;
Altintas, L ;
Karaman, A .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2002, 16 (04) :347-352
[2]   Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis [J].
Allanore, Y ;
Kahan, A ;
Sellam, J ;
Ekindjian, OG ;
Borderie, D .
CLINICA CHIMICA ACTA, 2006, 365 (1-2) :143-148
[3]  
ALONSO JCT, 1991, BRIT J RHEUMATOL, V30, P245
[4]  
AUSTIN RC, 2004, CELL DEATH DIFFER S1, V11
[5]   Why visceral fat is bad: Mechanisms of the metabolic syndrome [J].
Bergman, Richard N. ;
Kim, Stella P. ;
Catalano, Karyn J. ;
Hsu, Isabel R. ;
Chiu, Jenny D. ;
Kabir, Morvarid ;
Hucking, Katrin ;
Ader, Marilyn .
OBESITY, 2006, 14 :16S-19S
[6]   The clustering of other chronic inflammatory diseases in inflammatory bowel disease: A population-based study [J].
Bernstein, CN ;
Wajda, A ;
Blanchard, JF .
GASTROENTEROLOGY, 2005, 129 (03) :827-836
[7]   Effects of etanercept in patients with the metabolic syndrome [J].
Bernstein, LE ;
Berry, J ;
Kim, S ;
Canavan, B ;
Grinspoon, SK .
ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (08) :902-908
[8]   Quality of life in patients with psoriasis [J].
Bhosle, Monali J. ;
Kulkarni, Amit ;
Feldman, Steven R. ;
Balkrishnan, Rajesh .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2006, 4 (1)
[9]  
Boden G, 2001, Endocr Pract, V7, P44
[10]   Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden [J].
Boffetta, P ;
Gridley, G ;
Lindelöf, B .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (06) :1531-1537